DSGN Stock News & Analysis | Latest Updates

Design Therapeutics Appoints Justin Gover to Board of Directors

(NASDAQ:DSGN) CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately.

September 10, 2025Board

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

DSGN

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York.

August 27, 2025Conference

Design Therapeutics Submitted An Investigational New Drug Application For DT-216P2 With The FDA, The Company Received A Clinical Hold Notice On The IND Application From FDA Noting Nonclinical Deficiencies

DSGN

June 4, 2025

Design Therapeutics Announced That The First Friedreich Ataxia Patient Has Been Dosed Via Intravenous Infusion In Its RESTORE-FA Open-label Phase 1/2 Multiple-ascending Dose Trial Of Dt-216P2, Initial Data from the Ongoing, Blinded Phase 1 Single-Ascendin

DSGN

June 4, 2025

Design Therapeutics Q1 EPS $(0.31) Misses $(0.28) Estimate

DSGN

May 7, 2025

Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker Trial For Patients With Fuchs Endothelial Corneal Dystrophy

DSGN

May 1, 2025

Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025

DSGN

April 21, 2025

Design Therapeutics Expects Cash And Equivalents Of $245.5M As Of December 31, 2024, To Fund Its Planned Operating Expenses Into 2029

DSGN

March 10, 2025

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

DSGN

March 10, 2025

RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30

DSGN

May 2, 2022

DSGN News

Design Therapeutics Appoints Justin Gover to Board of Directors

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Design Therapeutics Submitted An Investigational New Drug Application For DT-216P2 With The FDA, The Company Received A Clinical Hold Notice On The IND Application From FDA Noting Nonclinical Deficiencies

Design Therapeutics Announced That The First Friedreich Ataxia Patient Has Been Dosed Via Intravenous Infusion In Its RESTORE-FA Open-label Phase 1/2 Multiple-ascending Dose Trial Of Dt-216P2, Initial Data from the Ongoing, Blinded Phase 1 Single-Ascendin

Design Therapeutics Q1 EPS $(0.31) Misses $(0.28) Estimate

Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker Trial For Patients With Fuchs Endothelial Corneal Dystrophy

Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025

Design Therapeutics Expects Cash And Equivalents Of $245.5M As Of December 31, 2024, To Fund Its Planned Operating Expenses Into 2029

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30